Court Report -- November 18, 2012

by McDonnell Boehnen Hulbert & Berghoff LLP
Contact

[author: Sherri Oslick]

Gavel About Court Report:  Each week we will report briefly on recently filed biotech and pharma cases.

New England Biolabs, Inc. et al. v. Enzymatics, Inc.
1:12-cv-12125; filed November 14, 2012 in the District Court of Massachusetts

• Plaintiffs:  New England Biolabs, Inc.; SomaLogic, Inc.; Gilead Sciences, Inc.
• Defendant:  Enzymatics, Inc.

Infringement of U.S. Patent Nos. 5,670,637 ("Nucleic Acid Ligands," issued September 23, 1997) and 5,874,557 ("Nucleic Acid Ligand Inhibitors to DNA Polymerase," issued February 23, 1999) based on Enzymatics' manufacture, use, offers for sale, and sale of various DNA polymerases, including, Taq DSC 2.0 DNA Polymerase.  View the complaint here.

Angros v. Ventana Medical Systems Inc.
5:12-cv-01262; filed November 14, 2012 in the Western District of Oklahoma

Infringement of U.S. Patent Nos. 7,476,362 ("In Situ Heat Induced Antigen Recovery and Staining Apparatus and Method," issued January 13, 2009), 7,632,461 (same title, issued December 15, 2009), 8,007,720 (same title, issued August 30, 2011), 8,007,721 (same title, issued August 30, 2011), 8,052,927 (same title, issued November 8, 2011), 8,071,023 (same title, issued December 6, 2011), and 8,092,742 (same title, issued January 10, 2012) based on Ventana's manufacture, use, offers for sale, and sale of products embodying the patented inventions.  View the complaint here.

Merck Sharp & Dohme Corp. et al. v. APP Pharmaceuticals Inc. et al.
1:12-cv-01410; filed November 9, 2012 in the District Court of Delaware

• Plaintiffs:  Merck Sharp & Dohme Corp.; Millennium Pharmaceuticals Inc.
• Defendants:  APP Pharmaceuticals Inc.; APP Pharmaceuticals LLC; Fresenius Kabi Pharmaceuticals Holding Inc.; Fresenius Kabi USA Inc.; Fresenius Kabi USA LLC

Infringement of U.S. Patent Nos. 5,807,825 ("Platelet Aggregation Inhibitors," issued September 15, 1998), 5,747,447 ("Stable Polypeptide Composition," issued May 5, 1998) and 5,968,902 ("Platelet Aggregation Inhibitors," issued October 19, 1999), licensed to Merck, following a Paragraph IV certification as part of APP's filing of an ANDA to manufacture a generic version of Merck's Integrilin® (eptifibatide injection, used to treat acute coronary syndrome).  View the complaint here.

Ferring B.V. v. Watson Pharmaceuticals, Inc. et al.
2:12-cv-01935; filed November 9, 2012 in the District Court of Nevada

• Plaintiff:  Ferring B.V.
• Defendants:  Watson Pharmaceuticals, Inc.; Watson Laboratories, Inc.; Watson Laboratories, Inc. – Florida; Watson Pharma, Inc.

Ferring B.V. v. Apotex, Inc. et al.
2:12-cv-01941; filed November 9, 2012 in the District Court of Nevada

• Plaintiff:  Ferring B.V.
• Defendants:  Apotex, Inc.; Apotex Corp.

The complaints in these cases are substantially identical.  Infringement of U.S. Patent No. 8,273,795 ("Tranexamic Acid Formulations," issued September 25, 2012) following a Paragraph IV certification as part of defendants' filing of an ANDA to manufacture a generic version of Ferring's Lysteda® (tranexamic acid, used to treat heavy menstrual bleeding).  View the Watson complaint here.

Exelixis, Inc. v. Kappos
1:12-cv-01284; filed November 9, 2012 in the Eastern District of VirginiA

Review and correction of the patent term adjustment calculation made by the U.S. Patent and Trademark Office for U.S. Patent No. 8,178,532 ("c-Met Modulators and Method of Use," issued May 15, 2012).  View the complaint here.

AbbVie Inc. et al. v. Watson Pharmaceuticals Inc. et al.
1:12-cv-01409; filed November 8, 2012 in the District Court of Delaware

• Plaintiffs:  AbbVie Inc.; Abbott Respiratory LLC
• Defendants:  Watson Pharmaceuticals Inc.; Watson Laboratories Inc. – Florida; Watson Pharma Inc.

Infringement of U.S. Patent Nos. 6,080,428 ("Nicotinic Acid Compositions for Treating Hyperlipidemia and Related Methods Therefor," issued June 27, 2000) and 6,469,035 ("Methods of Pretreating Hyperlipidemic Individuals with a Flush Inhibiting Agent Prior to the Start of Single Daily Dose Nicotinic Acid Therapy to Reduce Flushing Provoked by Nicotinic Acid," issued October 22, 2002) following a Paragraph IV certification as part of Watson's filing of an ANDA to manufacture a generic version of Abbott's Niaspan® (niacin extended-release tablets, used to treat hypercholesterolemia).  View the complaint here.

 

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© McDonnell Boehnen Hulbert & Berghoff LLP | Attorney Advertising

Written by:

McDonnell Boehnen Hulbert & Berghoff LLP
Contact
more
less

McDonnell Boehnen Hulbert & Berghoff LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Privacy Policy (Updated: October 8, 2015):
hide

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.

Security

JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.
Feedback? Tell us what you think of the new jdsupra.com!